Myanmar

Reimbursed Care Access

Myanmar maintains a restrictive, control-oriented narcotics regime under its Narcotic Drugs and Psychotropic Substances Law (1993, amended) that allows use of controlled substances for registered medical treatment but criminalizes production, trafficking and unauthorised possession. Ketamine is used as an essential hospital anesthetic and is present in the country’s medical supply chain, while most classic psychedelics (psilocybin, MDMA, DMT, 5‑MeO‑DMT, ibogaine, ayahuasca, mescaline, 2C‑X) are treated as controlled/declared narcotic plants or psychotropic substances with no authorised medical access outside tightly controlled research or Ministry of Health permission. Evidence of esketamine (Spravato®) marketing or reimbursement in Myanmar is not found in national/regulatory sources; therefore it is not an established reimbursed therapy there.